EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment

Yasuyuki Okada, Yasushi Sato, Ryo Shinomiya, Takanori Miyake, Taku Takahashi, Reiko Yokoyama, Yasuhiro Mitsui, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Yutaka Kawano und 1 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02677-y ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Yasuyuki Okada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Liposomal irinotecan + fluorouracil/leucovorin (nal-IRI + 5FU/LV) is commonly used as a second- or later-line treatment for pancreatic ductal adenocarcinoma (PDAC) and offers survival benefits. However, its efficacy and safety in patients previously treated with FOLFIRINOX, which includes irinotecan, remain unclear. We evaluated the efficacy and safety of nal-IRI + 5FU/LV in patients with unresectable PDAC who received previous FOLFIRINOX therapy and those who did not. METHODS: This retrospective observational study included 42 patients with PDAC who were treated with nal-IRI + 5FU/LV (October 2020-November 2023). Patients were grouped based on prior FOLFIRINOX treatment. RESULTS: The progression-free survival (PFS) in patients who previously received modified FOLFIRINOX (mFFX) therapy was shorter than that in patients who did not (2.5 vs. 3.5 months, P = 0.07). When patients with greater than- and less than the cut-off value of irinotecan-free interval (IFI) were classified into the long and short IFI groups, respectively, PFS was significantly longer in the long-IFI group than that in the short IFI group (4.0 vs. 2.1 months, P = 0.01). Moreover, the C-reactive protein/albumin ratio (CAR) was also a significant predictor of PFS (P = 0.03). Furthermore, both factors were found to be independent factors influencing PFS in the univariate Cox regression analysis (P = 0.02 and P = 0.04). CONCLUSION: Nal-IRI + 5FU/LV therapy may be a safe and effective option as a second- or later-line treatment, particularly for patients who have not previously received mFFX therapy. For patients who received prior mFFX exposure, a longer IFI and lower CAR may indicate greater potential benefit, thus aiding in more personalized treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansLeucovorinFluorouracilIrinotecanMaleFemaleMiddle AgedAgedRetrospective StudiesOxaliplatinLiposomesAdultProgression-Free Survival

Stichwörter der Autor:innen

FOLFIRINOXIrinotecan-free intervalLiposomal irinotecanPancreatic ductal adenocarcinoma

Substanzen

LeucovorinFluorouracilIrinotecanfolfirinoxOxaliplatinLiposomes

Autor:innen und Institutionen

  • Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima, Japan.
  • Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima, Japan. sato.yasushi@tokusima-u.ac.jp.
  • Department of Community Medicine for Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. sato.yasushi@tokusima-u.ac.jp.

Zitieren

APA

Okada, Y., Sato, Y., Shinomiya, R., Miyake, T., Takahashi, T., Yokoyama, R., Mitsui, Y., Tomonari, T., Okamoto, K., Sogabe, M., Miyamoto, H., Kawano, Y., & Takayama, T. (2025). Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02677-y

Vancouver

Okada Y, Sato Y, Shinomiya R, Miyake T, Takahashi T, Yokoyama R, et al. Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02677-y

BibTeX
@article{Okada2025,
  author = {Okada, Yasuyuki and Sato, Yasushi and Shinomiya, Ryo and Miyake, Takanori and Takahashi, Taku and Yokoyama, Reiko and Mitsui, Yasuhiro and Tomonari, Tetsu and Okamoto, Koichi and Sogabe, Masahiro and Miyamoto, Hiroshi and Kawano, Yutaka and Takayama, Tetsuji},
  title = {Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02677-y}
}
Kostenlos starten →